Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total Liver Disease Franchise Product Sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
877
Period ended Jun 30, 2026
Change on a year earlier
+10.3%
795 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Liver Disease Franchise Product Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 877 | +10.3% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 767 | +1.2% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 845 | +17.5% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 819 | +11.7% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 795 | -4.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 758 | +2.8% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 719 | +4.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 733 | +3.8% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 832 | +17.0% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 737 | +9.2% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 691 | -0.4% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 706 | -10.4% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 711 | +4.3% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 675 | +6.3% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 694 | – | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 788 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 682 | – | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 635 | – | Form 10-Q (filed 2023-05-03) ↗ |
Breakdown
What makes up total liver disease franchise product sales ($m)
- Total Liver Disease Franchise Product Sales — U.S. sales ($M)433 · Q2 2026
- Total Liver Disease Franchise Product Sales — Europe sales ($M)193 · Q2 2026
- Total Liver Disease Franchise Product Sales — Rest of World sales ($M)251 · Q2 2026
- Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%)10.0% · Q2 2026
- Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) ($M)303 · Q2 2026
- Vemlidy (tenofovir alafenamide — HBV) ($M)289 · Q2 2026
- Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) ($M)118 · Q2 2026
- Total HCV Franchise (legacy sub-franchise breakout) ($M)432 · Q4 2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M)259 · Q4 2023
Cite this data
StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales ($M) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.